Honda HRC confirmed on 22 September that Joan Mir will miss Round 16, the Japanese Grand Prix, and Round 17, the Indonesian Grand Prix, of the 2026 MotoGP season. The decision followed advice from Dr Angel Charte and the medical team at Dexeus University Hospital in Barcelona. Tests had not yet established the cause. Mir will continue to rest, receive treatment and undergo further examinations.
Symptoms have lasted for months; investigations continue
According to Honda, Mir had experienced several symptoms for months, with a recent deterioration affecting his energy and racing performance. After retiring from the San Marino Grand Prix, he missed Austria and continued undergoing tests in Barcelona. The medical team hoped further examinations would identify the cause; the announcement did not give a definitive diagnosis.
Dr Charte recommended strict rest and rehabilitation for the next 15 days, ruling Mir out of Japan and Indonesia. The 15 days describe this phase of medical management. Honda did not identify the end of that period or any subsequent round as a confirmed comeback point, and his condition requires continued medical observation.
Chantra to substitute in Japan
On 23 September, MotoGP further confirmed that Somkiat Chantra would replace Mir for Honda HRC Castrol at the Japanese Grand Prix. That arrangement specifically covers Japan and does not establish a replacement for Indonesia. Mir will continue his recovery plan, with an official update on his condition expected after the Indonesian Grand Prix.
Chantra raced in MotoGP for LCR Honda in 2025 before moving to HRC’s WorldSBK programme in 2026. He won the Moto2 race at Motegi in 2023 and finished 15th in the 2025 Motegi MotoGP race on the Honda RC213V. That gives him prior race experience on a MotoGP bike at the circuit, while the Moto2 victory and premier-class result still require separate consideration.
INKA SPORTS analysis: confirming a substitute does not confirm a comeback date
The announcement concerns two processes at different stages: Mir’s investigations and recovery, and Honda’s race staffing. Confirming the Japanese replacement resolves who will compete there without changing the medical position that the cause remains unclear. Future assessments of Mir’s ability to return should follow new information from the team and clinicians. Neither the 15-day rest recommendation nor the planned update after Indonesia can be treated as a confirmed return date.
Summary
Mir’s absence from Japan and Indonesia is confirmed; the cause and timing of his return await further tests and announcements. Chantra’s Japanese substitute role gives Honda a clear entry arrangement, but its scope should not automatically extend to the next round. For Mir, the known priority remains completing the rest, treatment and examinations prescribed by the medical team.
